59 • Anemia screening on a routine basis for pregnant women; • Anxiety disorders screening in adolescent and adult women, including those who are pregnant or postpartum; • BRCA counseling about genetic testing for women at higher risk. Women whose family history is associated with an increased risk for deleterious mutations in BRCA 1 or BRCA 2 genes will receive referral for counseling. The Plan will also cover BRCA 1 or 2 genetic tests without cost-sharing, if appropriate as determined by the woman’s health care provider, including for a woman who has previously been diagnosed with cancer, as long as she is not currently symptomatic or receiving active treatment for breast, ovarian, tubal or peritoneal cancer; • For women at increased risk for breast cancer aged 35 years or older , risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects. • Breast cancer screening mammography for women with or without clinical breast examination and with or without diagnosis, every 1 to 2 years for women aged 40 to 74 years; • Breast cancer chemoprevention counseling for women at higher risk. The Plan will pay for counseling by physicians with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention, to discuss the risks and benefits of chemoprevention. The Plan will also pay for risk-reducing medications for women at increased risk for breast cancer and at low risk for adverse medication effects; • Interventions or referrals, during pregnancy and after birth, to support breastfeeding; • Low-dose aspirin after 12 weeks of gestation for women who are at high risk for preeclampsia; • Comprehensive lactation support and counseling by a trained provider during pregnancy and/or in the postpartum period, and costs for renting breastfeeding equipment. The Plan may pay for purchase of lactation equipment instead of rental, if deemed appropriate by the Plan; • Cervical cancer screening for women ages 21 to 65 with Pap smear every three years; • Human papillomavirus testing for women ages 30 and older with normal Pap smear results, once every three years as part of a well woman visit; • Chlamydia and gonorrhea infection screening for all sexually active women aged 24 and younger, and in woman 25 years or older who are at increased risk of infection; • For all pregnant women aged 24 and younger, and for older pregnant women at increased risk, chlamydia infection screening is covered as part of the prenatal visit; • For women of reproductive capacity, the Plan will cover at least one form of contraception in each of the FDA-approved contraceptive methods (including barrier and hormonal methods and implanted devices) as well as patient education and counseling, when prescribed by a health care provider. Services related to follow-up and management of side effects, counseling for continued adherence, and device removal are also covered without cost sharing. The FDA-approved contraception methods for women include: • Sterilization surgery (tubal ligation) • Surgical sterilization implant for women Implantable rod • Intrauterine device (IUD) copper